Literature DB >> 30816566

Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells.

Su In Lee1, Md Saiful Islam Roney1, Jong Hyeok Park1, Ji-Young Baek1, Jooyeon Park1, Sang Kyum Kim2, Song-Kyu Park1,3.   

Abstract

BACKGROUND: The objective of this study was to determine whether PC-3 human prostate cancer cell-derived cancer stem cells (CSC)-like cells grown in a regular cell culture plate not coated with a matrix molecule might be useful for finding differentiation-inducing agents that could alter properties of prostate CSC.
METHODS: Monolayer cells prepared from sphere culture of PC-3 cells were characterized for the presence of pluripotency and tumorigenicity. They were then applied to screen a compound library to find compounds that could induce morphology changes of cells. Mechanisms of action of compounds selected from the chemical library that induced the loss of pluripotency of cells were also investigated.
RESULTS: C5A cells prepared from PC-3 cell-derived sphere culture expressed pluripotency markers such as Oct4, Sox2, and Klf4. C5A cells were highly proliferative. They were invasive in vitro and tumorigenic in vivo. Some dopamine receptor antagonists such as thioridazine caused reduction of pluripotency markers and tumorigenicity. Thioridazine, unlike promazine, inhibited phosphorylation of AMPK in a dose dependent manner. BML-275, an AMPK inhibitor, also induced differentiation of C5A cells as seen with thioridazine whereas A769663, an AMPK activator, blocked its differentiation-inducing ability. Transfection of C5A cells with siRNAs of dopamine receptor subtypes revealed that knockdown of DRD2 or DRD4 induced morphology changes of C5A cells.
CONCLUSIONS: Some dopamine receptor antagonists such as thioridazine can induce differentiation of CSC-like cells by inhibiting phosphorylation of AMPK. Binding to DRD2 or DRD4 might have mediated the action of thioridazine involved in the differentiation of CSC-like cells.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  PC-3; cancer stem cell; differentiation; dopamine; pluripotency

Mesh:

Substances:

Year:  2019        PMID: 30816566     DOI: 10.1002/pros.23779

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

1.  Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis.

Authors:  Yanlin Song; Lu Li; Jiao Chen; Hongli Chen; Bomiao Cui; Yun Feng; Ping Zhang; Qiangsheng Zhang; Yong Xia; Min Luo
Journal:  Cell Cycle       Date:  2020-12-14       Impact factor: 4.534

2.  Targeting Cancer Stem Cells with Differentiation Agents as an Alternative to Genotoxic Chemotherapy for the Treatment of Malignant Testicular Germ Cell Tumors.

Authors:  Amanda R Loehr; Timothy M Pierpont; Eric Gelsleichter; Anabella Maria D Galang; Irma R Fernandez; Elizabeth S Moore; Matthew Z Guo; Andrew D Miller; Robert S Weiss
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

Review 3.  Regulation of the Cancer Stem Phenotype by Long Non-Coding RNAs.

Authors:  Jose Adan Gutierrez-Cruz; Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  Cells       Date:  2022-07-30       Impact factor: 7.666

4.  Establishment of a novel prognostic prediction model through bioinformatics analysis for prostate cancer based on ferroptosis-related genes and its application in immune cell infiltration.

Authors:  Bo-Yu Yang; Mei-Shan Zhao; Ming-Jun Shi; Jing-Cheng Lv; Ye Tian; Yi-Chen Zhu; Fang-Zhou Zhao; Xuan-Hao Li; Jian Song
Journal:  Transl Androl Urol       Date:  2022-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.